These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26725219)

  • 1. Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer.
    Lyons MD; Smith AB
    Urol Oncol; 2016 Jun; 34(6):262-70. PubMed ID: 26725219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimodal therapy for muscle-invasive bladder cancer.
    Mathes J; Rausch S; Todenhöfer T; Stenzl A
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?
    Cha EK; Donahue TF; Bochner BH
    Urol Clin North Am; 2015 May; 42(2):189-99, viii. PubMed ID: 25882561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
    Koga F; Kihara K
    Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.
    Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A
    Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer.
    McHaffie DR; Kruser TJ; Gaston K; Mahoney J; Graham D; Haake M
    Urol Oncol; 2016 Jun; 34(6):271-8. PubMed ID: 27108225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
    Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
    BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
    El-Taji OM; Alam S; Hussain SA
    Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral resection and partial cystectomy for invasive bladder cancer.
    Laufer M
    Semin Urol Oncol; 2000 Nov; 18(4):296-9. PubMed ID: 11101093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer.
    Kuczyk M; Machtens S; Bokemeyer C; Kollmannsberger C; Hartmann J; Kondoh M; Merseburger A; Jonas U
    World J Urol; 2002 Aug; 20(3):183-9. PubMed ID: 12196902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.
    Suer E; Hamidi N; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
    World J Urol; 2016 Jun; 34(6):847-51. PubMed ID: 26462931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organ-sparing treatment of bladder cancer].
    Niedworok C; Shaleva A; Rübben H; Stenzl A
    Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Johnson SB; Yu JB
    Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
    Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
    J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.